Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
80.36 USD | -0.33% | -2.12% | +4.45% |
May. 29 | UBS Adjusts DuPont de Nemours Price Target to $98 From $93, Maintains Buy Rating | MT |
May. 28 | DuPont's Breakup Plan Holds Logic Amid Disadvantages, BofA Says | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Sales forecast by analysts have been recently revised upwards.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- With a 2024 P/E ratio at 30.74 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- With an enterprise value anticipated at 3.19 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.45% | 33.71B | C | ||
+0.51% | 76.12B | B | ||
-2.92% | 46.57B | A- | ||
+12.78% | 18.26B | B | ||
+8.36% | 11.59B | A- | ||
-1.50% | 10.53B | - | ||
-22.54% | 10.2B | B | ||
-0.53% | 9.21B | A- | ||
-11.63% | 8.09B | C- | ||
-1.91% | 7.7B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DD Stock
- Ratings DuPont de Nemours, Inc.